To understand whether bevacizumab treatment impacts the immunological status of ovarian cancer patients, the modulation of circulating CD4 and CD8 T cells was firstly analyzed in the Bev group and the Ctrl group before (T0) and after III and VI cycles of treatments (Figure 1A). The gene discussed is CD8A; the disease is ovarian carcinoma.